[Federal Register Volume 61, Number 102 (Friday, May 24, 1996)]
[Notices]
[Pages 26188-26191]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-13177]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Advisory Committees; Notice of Meetings
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces forthcoming meetings of public advisory
committees of the Food and Drug Administration (FDA). This notice also
summarizes the procedures for the meetings and methods by which
interested persons may participate in open public hearings before FDA's
advisory committees.
FDA has established an Advisory Committee Information Hotline (the
hotline) using a voice-mail telephone system. The hotline provides the
public with access to the most current information on FDA advisory
committee meetings. The advisory committee hotline, which will
disseminate current information and information updates, can be
accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory
[[Page 26189]]
committee is assigned a 5-digit number. This 5-digit number will appear
in each individual notice of meeting. The hotline will enable the
public to obtain information about a particular advisory committee by
using the committee's 5-digit number. Information in the hotline is
preliminary and may change before a meeting is actually held. The
hotline will be updated when such changes are made.
MEETINGS: The following advisory committee meetings are announced: -
Ear, Nose, and Throat Devices Panel of the Medical Devices Advisory
Committee
Date, time, and place. June 11, 1996, 8:30 a.m., Corporate Bldg.,
conference room 020B, 9200 Corporate Blvd., Rockville, MD. A limited
number of overnight accommodations have been reserved at the Marriott
Courtyard Hotel, 2500 Research Blvd., Rockville, MD. Attendees
requiring overnight accommodations may contact the hotel at 301-670-
6700 and reference the FDA Panel meeting block. Reservations will be
confirmed at the group rate based on availability. Attendees with a
disability requiring special accommodations should notify the contact
person listed below. The availability of special accommodations cannot
be assured unless prior written notification is received.
Type of meeting and contact person. Open public hearing, 8:30 a.m.
to 9:45 a.m., unless public participation does not last that long; open
committee discussion, 9:45 a.m. to 4 p.m.; closed committee
deliberations, 4 p.m. to 5 p.m.; Marilyn N. Flack, Center for Devices
and Radiological Health (HFZ-470), Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850, 301-594-2080, or FDA Advisory
Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), Ear, Nose, and Throat Devices Panel, code 12522.
Please call the hotline for information concerning any possible
changes.
General function of the committee. The committee reviews and
evaluates data on the safety and effectiveness of marketed and
investigational devices and makes recommendations for their regulation.
Agenda--Open public hearing. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Those desiring to make formal presentations should
notify the contact person before May 29, 1996, and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time required to make their comments.
Open committee discussion. The committee will discuss a premarket
approval application that seeks to substantiate the safety and
effectiveness of a bronchoscope device utilizing autofluorescence to
aid in detection of abnormal lung tissue.
Closed committee deliberations. FDA staff will present to the
committee trade secret and/or confidential commercial information
regarding present and future FDA issues. This portion of the meeting
will be closed to permit discussion of this information (5 U.S.C.
552b(c)(4)).---
Oncologic Drugs Advisory Committee
Date, time, and place. June 13 and 14, 1996, 8:30 a.m., Holiday
Inn--Gaithersburg, Walker and Whetstone Rooms, Two Montgomery Village
Ave., Gaithersburg, MD.
Type of meeting and contact person. Open public hearing, June 13,
1996, 8:30 a.m. to 9:30 a.m., unless public participation does not last
that long; open committee discussion, 9:30 a.m. to 4:30 p.m.; open
committee discussion, June 14, 1996, 8:30 a.m. to 1 p.m.; closed
committee deliberations, 1 p.m. to 3:30 p.m.; Jannette O'Neill-
Gonzalez, Center for Drug Evaluation and Research (HFD-21), Food and
Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-
5455, or FDA Advisory Committee Information Hotline, 1-800-741-8138
(301-443-0572 in the Washington, DC area), Oncologic Drugs Advisory
Committee, code 12542. Please call the hotline for information
concerning any possible changes.
General function of the committee. The committee reviews and
evaluates data on the safety and effectiveness of marketed and
investigational human drugs for use in treatment of cancer.
Agenda--Open public hearing. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Those desiring to make formal presentations should
notify the contact person before June 7, 1996, and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time required to make their comments.
Open committee discussion. On June 13, 1996, the committee will
discuss: (1) New drug application (NDA) 20-571 CamptosarTM
(irinotecan hydrochloride injection, The Upjohn Co.), indicated for the
treatment of patients with metastatic carcinoma of the colon or rectum
whose disease has recurred or progressed following 5-FU-based therapy;
and (2) NDA 20-036/S-011 Aredia (pamidronate disodium for
injection, Ciba-Geigy Corp.), indicated for use in conjunction with
standard antineoplastic therapy for treatment of osteolytic bone
metastases. On the morning of June 14, 1996, the committee will discuss
NDA 20-637, Gliadel Wafer (polifeprosan 20 with carmustine,
Guilford Pharmaceuticals), indicated for use as an adjunct to surgery
to prolong survival in patients with a malignant glioma.
Closed committee deliberations. On the afternoon of June 14, 1996,
the committee will review trade secret and/or confidential commercial
information relevant to pending investigational new drug applications
and NDA's. This portion of the meeting will be closed to permit
discussion of this information (5 U.S.C. 552b(c)(4)).
Blood Products Advisory Committee
Date, time, and place. June 20 and 21, 1996, 8 a.m., Holiday Inn--
Bethesda, Versailles Ballrooms II and III, 8120 Wisconsin Ave.,
Bethesda, MD.
Type of meeting and contact person. Open committee discussion, June
20, 1996, 8 a.m. to 11 a.m.; open public hearing, 11 a.m. to 11:30
a.m., unless public participation does not last that long; open
committee discussion, 11:30 a.m. to 1:30 p.m.; closed committee
deliberations, 1:30 p.m. to 2:30 p.m.; open committee discussion, 2:30
p.m. to 3:30 p.m.; open public hearing, 3:30 p.m. to 4 p.m., unless
public participation does not last that long; open committee
discussion, 4 p.m. to 5:30 p.m.; open committee discussion, June 21,
1996, 8 a.m. to 10:30 a.m.; open public hearing, 10:30 a.m. to 11:30
a.m., unless public participation does not last that long; open
committee discussion, 11:30 a.m. to 2:30 p.m.; open public hearing,
2:30 p.m. to 3 p.m., unless public participation does not last that
long; open committee discussion, 3 p.m. to 4 p.m.; Linda A. Smallwood,
Center for Biologics Evaluation and Research (HFM-350), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-3514,
or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), Blood Products Advisory Committee,
code 12388. Please call the hotline for information concerning any
possible changes.
[[Page 26190]]
General function of the committee. The committee reviews and
evaluates data on the safety and effectiveness, and appropriate use of
blood products intended for use in the diagnosis, prevention, or
treatment of human diseases.
Agenda--Open public hearing. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Those desiring to make formal presentations should
notify the contact person before June 14, 1996, and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time required to make their comments.
Open committee discussion. On the morning of June 20, 1996, updates
on relevant public health issues will be presented and an overview of
draft reviewer guidance for blood establishment computer software will
be presented and discussed. In the afternoon, there will be discussion
of use of hemoglobin solutions in fluid rescuscitation from hemorrhagic
shock; in particular, issues in clinical trials. On the morning of June
21, 1996, proposed revisions to the human immunodeficiency virus (HIV)
re-entry algorithm will be reviewed and discussed. In the afternoon,
the Calypte Laboratories test for anti-HIV in urine will be presented
and discussed.
Closed committee deliberations. On June 20, 1996, the committee
will review trade secret and/or confidential commercial information
relevant to current or pending products. This portion of the meeting
will be closed to permit discussion of this information (5 U.S.C.
552b(c)(4)).
Each public advisory committee meeting listed above may have as
many as four separable portions: (1) An open public hearing, (2) an
open committee discussion, (3) a closed presentation of data, and (4) a
closed committee deliberation. Every advisory committee meeting shall
have an open public hearing portion. Whether or not it also includes
any of the other three portions will depend upon the specific meeting
involved. The dates and times reserved for the separate portions of
each committee meeting are listed above.
The open public hearing portion of each meeting shall be at least 1
hour long unless public participation does not last that long. It is
emphasized, however, that the 1 hour time limit for an open public
hearing represents a minimum rather than a maximum time for public
participation, and an open public hearing may last for whatever longer
period the committee chairperson determines will facilitate the
committee's work.
Public hearings are subject to FDA's guideline (subpart C of 21 CFR
part 10) concerning the policy and procedures for electronic media
coverage of FDA's public administrative proceedings, including hearings
before public advisory committees under 21 CFR part 14. Under 21 CFR
10.205, representatives of the electronic media may be permitted,
subject to certain limitations, to videotape, film, or otherwise record
FDA's public administrative proceedings, including presentations by
participants.
Meetings of advisory committees shall be conducted, insofar as is
practical, in accordance with the agenda published in this Federal
Register notice. Changes in the agenda will be announced at the
beginning of the open portion of a meeting.
Any interested person who wishes to be assured of the right to make
an oral presentation at the open public hearing portion of a meeting
shall inform the contact person listed above, either orally or in
writing, prior to the meeting. Any person attending the hearing who
does not in advance of the meeting request an opportunity to speak will
be allowed to make an oral presentation at the hearing's conclusion, if
time permits, at the chairperson's discretion.
The agenda, the questions to be addressed by the committee, and a
current list of committee members will be available at the meeting
location on the day of the meeting.
Transcripts of the open portion of the meeting may be requested in
writing from the Freedom of Information Office (HFI-35), Food and Drug
Administration, 5600 Fishers Lane, rm. 12A-16, Rockville, MD 20857,
approximately 15 working days after the meeting, at a cost of 10 cents
per page. The transcript may be viewed at the Dockets Management Branch
(HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23,
Rockville, MD 20857, approximately 15 working days after the meeting,
between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary
minutes of the open portion of the meeting may be requested in writing
from the Freedom of Information Office (address above) beginning
approximately 90 days after the meeting.
The Commissioner has determined for the reasons stated that those
portions of the advisory committee meetings so designated in this
notice shall be closed. The Federal Advisory Committee Act (FACA) (5
U.S.C. app. 2, 10(d)), permits such closed advisory committee meetings
in certain circumstances. Those portions of a meeting designated as
closed, however, shall be closed for the shortest possible time,
consistent with the intent of the cited statutes.
The FACA, as amended, provides that a portion of a meeting may be
closed where the matter for discussion involves a trade secret;
commercial or financial information that is privileged or confidential;
information of a personal nature, disclosure of which would be a
clearly unwarranted invasion of personal privacy; investigatory files
compiled for law enforcement purposes; information the premature
disclosure of which would be likely to significantly frustrate
implementation of a proposed agency action; and information in certain
other instances not generally relevant to FDA matters.
Examples of portions of FDA advisory committee meetings that
ordinarily may be closed, where necessary and in accordance with FACA
criteria, include the review, discussion, and evaluation of drafts of
regulations or guidelines or similar preexisting internal agency
documents, but only if their premature disclosure is likely to
significantly frustrate implementation of proposed agency action;
review of trade secrets and confidential commercial or financial
information submitted to the agency; consideration of matters involving
investigatory files compiled for law enforcement purposes; and review
of matters, such as personnel records or individual patient records,
where disclosure would constitute a clearly unwarranted invasion of
personal privacy.
Examples of portions of FDA advisory committee meetings that
ordinarily shall not be closed include the review, discussion, and
evaluation of general preclinical and clinical test protocols and
procedures for a class of drugs or devices; consideration of labeling
requirements for a class of marketed drugs or devices; review of data
and information on specific investigational or marketed drugs and
devices that have previously been made public; presentation of any
other data or information that is not exempt from public disclosure
pursuant to the FACA, as amended; and, deliberation to formulate advice
and recommendations to the agency on matters that do not independently
justify closing.
This notice is issued under section 10(a)(1) and (a)(2) of the
Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations
(21 CFR part 14) on advisory committees.
[[Page 26191]]
Dated: May 20, 1996.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 96-13177 Filed 5-23-96; 8:45 am]
BILLING CODE 4160-01-F
